The longevity of pain after surgery is debilitating and limits the recovery of patients. AYX1 is a double-stranded, unprotected, 23 base-pair oligonucleotide designed to reduce acute post-surgical pain and prevent its chronification with a single intrathecal perioperative dose. AYX1 mimics the DNA sequence normally bound by EGR1 on chromosomes, a transcription factor transiently induced in the dorsal root ganglia-spinal cord network following a noxious input. AYX1 binds to EGR1 and prevents it from launching waves of gene regulation that are necessary to maintain pain over time. A formulation suitable for an intrathecal injection of AYX1 was developed, including a specific ratio of AYX1 and calcium so the ionic homeostasis of the cerebrospinal fluid is maintained and no impact on neuromuscular control is produced upon injection. A GLP toxicology study in naïve Sprague Dawley rats was conducted using 3 dose levels up to the maximum feasible dose. Clinical observations, neurobehavioral observations, clinical pathology and histopathology of the nervous system and peripheral tissues were conducted. An additional nonGLP study was conducted in the spared nerve injury model of chronic neuropathic pain in which EGR1 is induced in the dorsal root ganglia and spinal cord. Similar testing was performed, including a modified Irwin test to assess a potential impact of AYX1 on autonomic nervous system responses, locomotion, activity, arousal, sensorimotor, and neuromuscular function. No AYX1-related adverse events were observed in any of the studies and the no-observed-adverse-effect-level was judged to be the maximum feasible dose.
Postsurgical pain arises from a combination of mechanical/ incisional, inflammatory and neuropathic mechanisms. The transcription factor Early growth response protein 1 (EGR1) is a major integrator of those noxious mechanisms. It is transiently induced in the dorsal root ganglia (DRG)-spinal cord following a noxious injury such as surgery (Bojovic et al., 2015; Geranton et al., 2008; Herdegen et al., 1991; Herdegen and Leah, 1998; Kendall et al., 1994; Rahman et al., 2002) . Time course studies in the spinal cord showed EGR1 is detectable from approximately 30 min up to approximately 12 h following such stimulation (Bojovic et al., 2015; Geranton et al., 2008) . During its induction, EGR1 launches gene regulation across most gene categories identified to maintain neuronal hypersensitization and pain over time (James et al., 2005) . Consistent with this observation, knockout studies show that the absence of EGR1 leads to the absence or reduction of pain following an injury (Ko et al., 2005) . Additional knockout work showed that the absence of EGR1 has no impact on neuronal architecture (Jones et al., 2001) .
AYX1 is a DNA-decoy drug candidate: a 23 base-pair, doublestranded, oligonucleotide that mimics the DNA sequence bound by EGR1 on chromosomes. It is administered once in the lumbar intrathecal space just prior to surgery and locally inhibits EGR1 activity by preventing its binding to chromosomes and its capacity to regulate gene expression. AYX1 efficacy for preventing mechanical hypersensitivity and pain in rat models of chronic neuropathic and acute post-surgical pain models was detailed in a prior publication (Mamet et al., 2014) . AYX1 is under clinical development (clinicaltrial.gov NCT02807428).
Little information is available regarding the safety of oligonucleotides injected intrathecally (Evers et al., 2015; Miller et al., 2013) , especially the class of transcription factor decoy molecules. Nucleotide-based compounds are large molecules with a backbone containing a high number of negative charges and an inner core with positive charges and hydrophobic molecular interactions. As such, they are capable of a wide range of molecular interactions in vivo that can potentially interfere with tissue homeostasis and generate potential acute toxicity. We developed a formulation for AYX1 specifically to not interfere with the local cerebrospinal fluid (CSF) homeostasis upon intrathecal injection. Using this formulation, we characterized the toxicology of AYX1 when delivered as a single intrathecal bolus up to maximum feasible dose based on the limits of AYX1 solubility and of the volume of an intrathecal bolus injection. AYX1 toxicology was also characterized in a "disease" state when EGR1 expression is induced in the DRG-spinal cord network following a nerve injury. Those combined data showed that the intrathecal AYX1 formulation is well tolerated in rats up to the maximum feasible dose.
MATERIALS AND METHODS
Animals. Sprague Dawley rats, approximately 250-350 g, were obtained from Charles River Laboratories (Portage, Michigan) for the ADY-TX2 study and Harlan (Livermore, California) for the other studies. Male and/or female were used depending on the study.
Intrathecal Injections. AYX1 was delivered as a single percutaneous intrathecal bolus injection under anesthesia as previously described in Mamet et al. (2014) except in study ADY-TX2 in which it was delivered without anesthesia via a catheter inserted at the cisterna magna level and advanced toward the lumbar enlargement (approximately 8 cm). Injection volume was 20 ll.
Clinical Response Score Assay. After the injection of a given formulation, rats were allowed to recover from anesthesia, placed in a cage and clinical observations recorded for approximately 1 h. Using an AYX1 formulation with no counter-ion, thirteen spontaneous or evoked clinical signs that can occur following the delivery of AYX1 were identified: tail shaking, tail stiffness, tail wagging, hunched back, vocalization, agitation, freezing behavior, distress/seizure, rear/hindpaw, motor dysfunction, exaggerated vocalization following tail pinch, exaggerated escape following tail pinch, induced wagging/stiffness following tail pinch. For each tested formulation, the absence or presence of a sign was numerically recorded by 0 or 1 and the total sum equated to the formulation score (minimum ¼ 0, maximum ¼ 13). Formulation scores were compared with the score of a saline intrathecal injection. 29 total rats were used for the presented data, n ¼ 2-6 per condition.
Free and Bound Calcium Concentration Determination. Increasing concentrations of AYX1 and CaCl 2 were incubated for 30-60 min. For AYX1 concentrations up to approximately 40 mg/ ml, the amount of calcium remaining free was measured using 0-cresolphthalein, a dye binding to free calcium (Calcium Colorimetric Assay Kit, BioVision, California). For experiments using higher AYX1 concentration, free calcium was isolated using ultrafiltration centrifugal membranes (Amicon Ultra 0.5 ML 3KDA, Millipore) and its concentration measured using a calcium ion electrode (LIS-146CACM-XS, Lazar Research Lab, California). The quantity of calcium bound to AYX1 was calculated as the difference between the calcium introduced in the solution and the measured free calcium.
Toxicology Studies Dose Selection. A 3.3 mg AYX1 dose is a maximum feasible dose based upon formulation concentration (165 mg/ml) and dose-volume (20 ll) constraints. 1.7 and 2.6 mg AYX1 correspond to doses in the high range of the efficacious dose-range in rats, which spans from approximately 0.5 mg up to the maximum feasible dose (Mamet et al., 2014 (Mamet et al., , 2017 .
ADY-TX2 Toxicology Study (GLP).
Male and female rats were distributed in groups of 16 animals each dosed with 0, 1.7, 2.6, or 3.3 mg AYX1 to be followed for 3 or 30 days (64 animals/sex). Additional groups of 3 (0 mg) and 9 (1.7, 2.6, or 3.3 mg AYX1) animals per sex were dedicated to toxicokinetic (TK) assessments only (30 animals/sex). Toxicology assessments consisted of body weight (prior to dosing on the day of dosing, Day 3, Day 8, twice weekly thereafter and on the day of necropsy), clinical observations (prior to dosing, immediately following dosing, at 1 and 4 h postdosing, then daily), Functional Observational Battery (prior to dosing, 4 h postdose on Day 1 and on Day 2 for all animals and during Week 4 for Day 30 animals), quantitative food consumption (g/d basis for Day 3 animals, weekly for Day 30 animals), clinical pathology (at necropsy) and urinalysis. At the day of necropsy, animals were anesthetized, perfused via the left cardiac ventricle with heparinized 0.001% sodium nitrite in saline followed by 10% neutral buffered formalin. Gross necropsy was performed and organs weighed ("Supplemental Protocol Information" section). Sections of the cervical, thoracic, and lumbar spinal cord and brain were collected, embedded in paraffin and stained with Hematoxylin and Eosin (H&E) for all groups. The spinal cord from all groups was also stained with an anti-glial fibrillary acidic protein (anti-GFAP) antibody (marker of astrocyte activation) and the brains of the control and 3.3 mg groups were stained with Fluoro-Jade B (stain increasing the sensitivity of evaluating brain neuronal degeneration). Additional tissues from the control and the 3.3 mg groups were embedded in paraffin, sectioned and stained with H&E ("Supplemental Protocol Information" section). Sections were evaluated by a board-certified veterinary pathologist with specialized training in neuropathology. TK animals were followed for clinical observations and their blood was drawn from 1 to 720 min postdosing and CSF (cisterna magna) collected after the last sample collection. AYX1 was detected using a CapillaryGel-Electrophoresis-Hybridization method (CGEH).
ADY-SNITX1 Toxicology Study (NonGLP). Twenty-four male rats were allocated to 3 groups of 8 animals that received a single administration of 0, 1.7, or 3.3 mg AYX1. Similar to pharmacology studies to ensure a timely inhibition of EGR1 (Mamet et al, 2014) , spared nerve injury (SNI) was produced immediately after AYX1 administration on study Day 1 by making an incision, tightly ligating the tibial and common peroneal nerves and removing a portion of the corresponding nerve trunk (Decosterd and Woolf, 2000) . Toxicology assessments consisted of behavioral observations linked to autonomic nervous system responses, locomotion, activity, arousal, sensorimotor, and neuromuscular function using a modified version of the Irwin method prior to treatment/surgery and 3, 8, and 14 days thereafter. Clinical observations were performed prior to treatment/ surgery and then once daily. Observations for morbidity, mortality, and any injury including the surgical wound were conducted twice daily. Food and water were provided ad libitum and availability checked twice daily. Body weight and food consumption measurements were conducted weekly beginning on the day of treatment/surgery. The size of the SNI incision was measured after surgery and 1, 2, 4, 8, 10, and 14 days thereafter to assess the rate and extent of wound healing. On Day 15, animals were sedated, blood was collected for clinical pathology (hematology, coagulation, clinical chemistry) and perfusion was performed via the left cardiac ventricle with 0.9% saline and heparin followed by 4% paraformaldehyde. The spinal cord (L4-L6), the tibial nerve ipsi-lateral to the nerve injury and the skin around the surgical incision were collected and processed for microscopic evaluation. The skin was stained with H&E, the spinal cord with H&E, Luxol Fast Blue (myelin stain) and immunolabeled with a GFAP antibody. The tibial branch of the sciatic nerve was post-fixed with Osmium and stained with H&E. Histopathology was performed by a board-certified veterinary pathologist with training in neuropathology.
Statistical Analysis. In the ADY-TX2 study, body weights, food consumption, clinical pathology, and organ weights were analyzed by a 1-way ANOVA, comparisons of the control group to other groups by Dunnett's test. Analysis was 2-tailed for significance levels of 5% and 1%. In the ADY-SNITX1 study, data were assessed for normality using the Kolmogorov-Smirnov test. If data were normally distributed, parametric analyses were performed. If not, nonparametric tests were conducted. As necessary, posthoc analyses were performed with Bonferonni (normal distribution) or Dunn's (nonnormal distribution) tests. A nonparametric Student t-test, followed by a T-Welsh analysis for uneven variance correction was used as needed.
Supplemental Protocol Information. Includes toxicology studies' regulatory compliance and animal welfare statements and protocol details on animal randomization, collected organs, histopathology, clinical observations, neurobehavioral examination, body weight, food uptake, ophthalmological examination, AYX1 chemistry, AYX1 CGEH assay, and the incisional model of pain testing.
RESULTS

AYX1 Formulation Development
AYX1 was initially formulated in 10 mM Tris pH8, 1 mM EDTA, 50 mM NaCl, a routine formulation for in vitro experiments. However, it was observed that contrary to vehicle injections, transient clinical signs of neuromuscular nature could occur following injection of this formulation of AYX1 in rats. Effects intensity varied with AYX1 dose from slight (eg, tail movement) to more severe adverse events (eg, hunched back). Those effects occurred from approximately 5-15 min following administration and lasted for approximately 30-60 min. It was hypothesized that AYX1 could bind ions necessary for the homeostasis of the intrathecal space and the control of neuro-motor reflexes. Based on the chemical composition of the CSF, the co-injection of AYX1 in Tris or sodium phosphate buffers with several counter-ions was tested, including Na . Results indicated that adding calcium to the AYX1 formulation could prevent the occurrence of the clinical signs. A systematic screening methodology (see "Materials and Methods" section) was developed to determine the appropriate ratio of calcium (CaCl 2 .2H 2 0, mw ¼ 147.02 g/mol) relative to AYX1 (14 092.92 g/mol) that eliminated these effects. In an iterative manner, formulations of AYX1 at a concentration close to the projected clinical concentration (approximately 100 mg/ml) containing increasing amounts of CaCl 2 were adjusted for isotonicity with NaCl and tested against saline, which is a standard control for rat intrathecal toxicology studies (Chiari et al., 1999; Yaksh et al., 2004 Yaksh et al., , 2014 . The physical effects associated with injecting a solution in the intrathecal space, including saline, can trigger clinical signs (Furuhama et al., 1997) . As such, saline produced a low clinical score ( Figure 1A ) but its injection was not completely devoid of clinical signs and triggered depending on the animal, tail shaking, tail stiffness, pinch-induced tail wagging/stiffness, rear/hindpaw agitation and hunched-backs reaction. The target outcome for AYX1 formulation was to produce a clinical score at least similar to saline but if feasible, a lower score with a minimum or no clinical sign in order to maximize safety in patients. Clinical scores were similar to saline starting at AYX1:CaCl 2 weight ratio of 1: 0.002 and significantly eliminated compared with saline at a weight ratio of 1:0.0146 g (molar ratio of 1:1.4 M) ( Figure 1A ). The latter only produced a low occurrence of tail stiffness and pinch-induced tail wagging/stiffness, the minimum observed signs in our hand following an intrathecal administration, and as such was preferred over lower ratios. A fixed weight ratio of AYX1: CaCl2 of 1:0.0198 6 0.003 (molar ratio of 1:1.8 6 0.3 M) was ultimately selected to account for manufacturing variability and to ensure the actual ratio would always be above 1:0.0146. Further experiments showed that injecting a single-strand version of AYX1 also produced clinical reactions, highlighting a probable class-effect for nucleotide-based compounds ( Figure 1A ).
AYX1-Calcium-Binding Relationship
Depending on AYX1 concentration, the concentration of total calcium introduced in the formulation could exceed the intrinsic CSF concentration, which would be undesirable since an excess of CSF calcium can produce hypothermia (Myers and Yaksh, 1971) . Experiments were conducted to characterize the AYX1:calcium binding relationship and the amount of calcium that remains free in the formulation at increasing concentrations of AYX1. Formulations containing 1.4-to 250-fold excess of calcium relative to AYX1 were prepared and free calcium measured ( Figure 1B ). The quantity of calcium binding AYX1 follows a positive linear relationship (the more calcium is added, the more binds to AYX1) until a plateau of binding saturation is reached. Calcium binding was influenced by the ionic strength of the solution, which was modulated by adding NaCl: the higher the ionic strength, the higher the calcium binding ( Figure 1B ). These results indicated that overall only a small portion of the calcium remains free in the presence of AYX1 in these formulations. Due to technical constraints linked to calcium detection assays, those initial experiments were conducted with concentrations of AYX1 below approximately 40 mg/ml. A complementary technique allowing testing with higher AYX1 concentrations confirmed that up to the solubility limit at small volumes (approximately 190 mg/ml), the amount of calcium that remained free was minimal relative to the concentration initially introduced in the formulation and within range of the endogenous CSF concentration at the 1:0.0198 ratio ( Figure 1C ). Those data confirmed that the selected AYX1:CaCl 2 weight ratio of 1:0.0198 is adequate for preventing clinical reactions upon intrathecal injection. A binding experiment using an EGR1 ELISA assay as described before (Mamet et al., 2014) showed that the presence of calcium does not interfere with the binding of AYX1 to EGR1 ( Figure 1D ). Consistent with this finding, the presence of calcium did not impact AYX1 efficacy when measured in the incisional model of pain following a 2.8 mg dose ( Figure 1E ).
Formulation Stability
Stability of formulations was evaluated visually, by sizeexclusion and ion-exchange HPLC and tested for pH up to 3 months at 5 C, 25 C, and 40 C. The initial screening to select AYX1 counter-ion was performed with either Tris 10 mM or Na 3 PO 4 5 mM buffers. Stability limitations were found between AYX1 and sodium phosphate solutions: low concentrations of sodium phosphate (<5 mM) did not provide adequate buffering to maintain pH, while higher concentrations ( 5 mM) resulted in visible precipitation, presumably due to the formation of AYX1 affinity for EGR1 in presence of calcium. AYX1-binding affinity for its target EGR1 was measured using a competition ELISA assay as described before (Mamet et al, 2014) . Briefly, a biotinylated EGR1 consensus tandem oligonucleotide (12 pmoles) is bound to the ELISA plate and incubated with nuclear protein extracts containing EGR1 in absence (white bar) or presence (black bars) of 100 pmoles of free competitor AYX1 including various fold excess molar ratios of CaCl 2 . The decrease of binding in presence of the free AYX1 competitor shows AYX1 affinity level for EGR1; E, AYX1 efficacy in the incisional model of pain in presence or absence of calcium. 2.8 mg AYX1 was formulated in Tris 10 mM with or without 14 mM Cacl2 (1:0.0146 weight ratio, 1:1.4 molar ratio) and injected once just before surgery in the incisional model of pain. AYX1 without Cacl 2 was compared to a Tris 10 mM vehicle (white bar) and AYX1 with Cacl 2 to a Tris 10 mM, 14 mM CaCl 2 vehicle (black bar). Comparison to the combined vehicles is also provided (left gray and shaded bars). Pain was assessed using repeat von Frey testing. Pain inhibition was measured as the reduction of areaunder-the curve of the total von Frey responses for AYX1-treated groups over vehicle-treated groups during the 2 days study period following surgery. Mean þ SEM, t-test, different from vehicle (area-under-the-curve), *p < .05, n ¼ 2-5 rats per condition.
calcium phosphate (Supplementary Table 1 ). On the other hand, 10 mM Tris was stable at pH 7.5 and no physical compatibility issues were observed with AYX1 and calcium (Supplementary Table 2 ). Thus the formulation selected to advance AYX1 in toxicology studies and clinical development contained calcium at a 1:0.0198 weight ratio, Tris 10 mM pH7.5, and NaCl for isotonicity.
Single Dose AYX1 GLP Toxicity Study in Rat (ADY-TX2 Study)
The goal of this GLP toxicity study was to determine the tolerability and potential toxicities of a single intrathecal injection of AYX1 in rats. No mortality associated with AYX1 was identified. Table 4 . No AYX1-related effects upon organ weight or gross pathology were noted. AYX1 injection had no associated microscopic tissue alterations. A catheter tract was observed in at least 1 section of the spinal cord (cervical, thoracic, or lumbar) at sacrifice Day 3 in 60 of 64 animals, including controls. Changes in severity and incidence of histologic findings varied between groups, but no correlation was found between those changes and increasing AYX1 concentrations. Microscopic findings were primarily associated with the catheter tract and included compression of the spinal cord with few incidences of nerve fiber degeneration and inflammation. Microscopic lesions not associated with the catheter tract were varied and inconsistent. Microscopic changes were limited to the spinal cord in all groups, with 1 exception: a male in the 1.7 mg dose group had a meningeal infiltrate of inflammatory cells in the brain that was minimal in severity. Microscopic changes in tissues other than the central nervous system in control and 3.3 mg animals were sporadic and incidental findings not correlated to AYX1 (eg, liver mononuclear cell infiltrate, esophagus mixed cells infiltrate). Similarly for Day 30 animals, microscopic findings were primarily associated with the catheter tract and included compression of the spinal cord. The incidence of microscopic findings appeared more elevated in males compared with females at both days but this was also reflected in the control groups. AYX1 groups were not different from their respective controls in each sex and the apparent difference may be attributed to catheter surgery. Overall at Days 3 and 30, the changes in severity and incidence varied between groups but no correlation was observed between microscopic changes and increasing AYX1 doses and/or sex. Microscopic changes observed in the lumbar spinal cord for Days 3 and 30 animals are presented Table 2 (males) and Supplementary Table 5 (females). In conclusion, AYX1 dosed at 1.7, 2.6 and 3.3 mg was well-tolerated, did not produce related clinical effects in-life, and was not associated with histopathologic alterations. Based upon the results of this study, the NoObserved-Adverse-Effect-Level (NOAEL) for a single intrathecal administration of AYX1 was considered to be at least 3.3 mg (165 mg/ml), the highest dose tested in this study. CSF and plasma sampling confirmed appropriate dosing and an exposure elevated in the CSF compared to the plasma (eg, AYX1 C max in the CSF of male rats was 4.8 mg/ml for the 3.3 mg dose vs 0.001 mg/ml in the plasma). "Total AYX1" concentrations (full length AYX1 plus metabolites, see "Supplemental Protocol Information" section) in the cisterna magna CSF generally increased with dose (Supplementary Table 6 ). In that compartment, T max ranged from 10 to 60 min and C max from approximately 1.4 to approximately 4.8 mg/ml. In the plasma, Total AYX1 concentrations ranged from approximately 0.0007 to approximately 0.001 mg/ml and T max from 10 to 30 min. No notable TK difference was observed between males and females.
Single Dose AYX1 Toxicity Study in the SNI Model of Pain (ADY-SNITX1 Study) The goal of this study was to determine the potential toxicity of a single injection of AYX1 in rats where EGR1 expression is induced by a nerve injury using the SNI model of pain in which AYX1 is pharmacologically active (Mamet et al, 2014) . There was no mortality in the study. No significant observations were noted on the skin, fur, ears, nose, mouth and back, or in respiratory, circulatory or autonomic functions. As an illustration of outcomes, results of the Irwin test are presented in Supplementary Table 7a-c. Clinical pathology (Supplementary Table 8 ) suggested lower neutrophil levels and higher lymphocyte levels in animals from the 1.7 mg group compared to the 3.3 mg group. However, those changes were within range of the standard deviation of vehicle-treated animals. Since no dose response could be established, these changes were considered incidental and not related to AYX1.
Histopathologic evaluation of the skin, spinal cord and tibial nerves for all groups is provided Supplementary Table 9. SNI surgery produced variable but sometimes pronounced nerve fiber degeneration in all groups (Figure 2 ). Local inflammation associated with the nerve ligation was present in all tibial nerve sections where the suture material was present as well as in several other animals in the 3.3 mg AYX1 group. The incidence and average severity of nerve fiber degeneration was equal across all groups in the distal segment of the tibial nerve, including controls. In the proximal segment of the tibial nerve, there was some indication of a decrease, on average, of nerve fiber degeneration in the proximal portion of the nerve in the animals treated with 3.3 mg AYX1 compared with all other groups. However, the semi-quantitative nature of this morphologic investigation was not sufficient with draw a conclusion from this difference. The degree of nerve fiber degeneration varied across animals within each group, likely due to the variability of the nerve ligation/section inherent to the SNI model. For instance, in the control group, 5/8 animals had severe nerve fiber degeneration in the distal portion of the nerve but 3/8 had only slight or no degeneration and similar incidences were found in the AYX1-treated groups. There were no changes in any of the spinal cord segments from any of the animals. There was no indication of astrocyte reaction as determined by GFAP labeling or alteration of myelin as determined by Luxol Fast Blue staining.
Since EGR1 is involved in wound healing (Wu et al., 2009) , the effect of AYX1 on the healing of the SNI surgical wound was assessed. No difference in the extent or rate and quality of wound closure was evident across the treatment groups. Minimally increased inflammation on average was noted in the 3.3 mg AYX1 group but this difference was interpreted to reflect biologic variability in wound healing. Based upon the results of this study, a NOAEL of at least 3.3 mg (165 mg/ml) was established for an intrathecal bolus of AYX1 in a rat model of nerve injury.
DISCUSSION
Initial AYX1 in vivo experiments were conducted using a Tris-EDTA and NaCl based formulation that was used with prior in vitro assays. This formulation was not suitable for intrathecal use as upon administration, some rats developed acute, transient clinical neuromuscular reactions. Since AYX1 is a large molecule, it was hypothesized that it could bind to and reduce the local CSF concentration of 1 or more ions involved in the control of neuromuscular reflexes, triggering the observed reactions. Adding calcium at an AYX1:CaCl 2 weight ratio of 1:0.0146 eliminated the occurrence of these signs using approximately 100 mg/ml AYX1. This formulation produced a better outcome than saline, presumably because saline can dilute the local CSF calcium by displacement upon injection while AYX1 formulation can compensate for such effect as it carries free calcium within range of the endogenous CSF calcium concentration. The absence of clinical signs using the 1:0.0198 ratio, that was ultimately selected to account for manufacturing variability, was confirmed in further toxicology studies using AYX1 up to its maximum feasible concentration and dose. Mg 2þ was also tested as a potential counter-ion: while it did reduce the occurrence of clinical signs at elevated ratios over AYX1, it was not chosen as it produces analgesic effects on its own (Bahar et al., 1996) . In essence, it was hypothesized that Mg 2þ could be masking instead of treating the source of the acute reactions triggered by AYX1. On the other hand, intrathecal injections of EDTA or EGTA calcium chelators have been described to induce hind limb tetanic contraction in mice in a dose-response fashion (Hornfeldt and Larson, 1990) , supporting the fact that the reduction of local CSF calcium concentration was the source of the reactions that were observed with the initial formulation of AYX1. AYX1 efficacy is measured as a reduction of mechanical hypersensitivity following an injury compared to control and is not impacted by the presence or the absence of calcium. This is consistent, on one hand, with the absence of interference of calcium on AYX1 binding to EGR1 and on the other hand, with the fact that the neuromuscular signs occurring without calcium are almost immediate and transient (approximately 30-60 min) following injection while AYX1 efficacy is delayed (approximately 24 h) and long-lasting (weeks-month) as described previously (Mamet et al., 2014) .
In rat toxicology studies, the clinical formulation of AYX1 containing calcium was well tolerated when given as a single dose up to a maximum feasible dose of 3.3 mg, defined by a maximum feasible concentration of 165 mg/ml and maximum intrathecal dose volume of 20 ll. In naïve rats, no evidence of AYX1-mediated untoward effects was seen within clinical, biochemical and anatomical assessments in peripheral tissues, the brain or locally within the spinal cord and DRG. Consistent with those observations, detailed neurobehavioral evaluations did not reveal evidence of AYX1-related toxicity. This was further supported by the absence of dose response effects. TK measurements showed an increased Total AYX1 concentration in the cisterna magna CSF with dose level, confirming appropriate animal dosing. Further, the low exposure of Total AYX1 in the plasma versus CSF is consistent with the expected exposure pattern following an intrathecal administration. Similar outcomes were observed in rats in which AYX1 pharmacological target, EGR1, was induced by nerve injury in the spinal cord and DRG. These data suggest that the toxicology profile of AYX1 is similar under low basal expression of EGR1 and conditions involving its increased local expression. In conclusion, the AYX1 maximum feasible dose in its clinical formulation was judged to be the NOAEL in rats, which represents approximately a 3.3-fold margin over AYX1 maximum efficacy dose of approximately 1 mg in rat models of pain (Mamet et al., 2017) . This data served as the basis to establish an appropriate margin of safety for human dose levels, based on a projected lumbar CSF exposure in human derived from volume of IT delivery, estimated CSF volumes in each species and complementary results from AYX1 pharmacokinetics in the lumbar CSF and AYX1 toxicology in dogs (not shown).
FUTURE DIRECTIONS
In this work, AYX1 was dosed once to reflect the fact that in patients it is injected only once for a given surgery. However one patient could undergo several surgeries and could be treated more than once with AYX1 over time. Thus testing repeat-dosing in rats could expand the characterization of AYX1 toxicology. Further, while the current work does not suggest AYX1 triggers an immune reaction, testing its immunogenicity directly might be envisioned.
SUPPLEMENTARY DATA
Supplementary data are available at Toxicological Sciences online. Figure 2 . Illustration of H&E staining images of the tibial nerve in the ADY-SNITX1 study. A, Vehicle; B, AYX1 1.7 mg; C, AYX1 3.3 mg. Each picture represents a section of the severed/ligated tibial nerve from a different animal and illustrates the variation of nerve degeneration observed within each study group. Animals were sacrificed 14 days following SNI surgery, tibial nerve sections collected and stained with H&E as described in the "Materials and Methods" section. , 2017, Vol. 159, No. 1 
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